Hyun Ho Choi1, Jung Jun Lee2, Young Dae Cho2, Moon Hee Han2,3, Won-Sang Cho3, Jeong Eun Kim3, Sang Joon An2, Jong Hyeon Mun3, Dong Hyun Yoo2, Hyun-Seung Kang3. 1. Department of Neurosurgery, Dongk-uk University Hospital, Dongkuk Unive-rsity College of Medicine, Ilsan, Korea. 2. Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. 3. Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Abstract
BACKGROUND: The use of antiplatelet medications to prevent thrombosis in the treatment of cerebral aneurysms with stents has become widely emphasized. OBJECTIVE: To compare low-dose prasugrel with clopidogrel in stent-assisted coil embolization of intracranial aneurysms. METHODS: This is a retrospective review of 311 aneurysms from 297 patients who underwent stent-assisted endovascular coil embolization of unruptured intracranial aneurysm between November 2014 and March 2017. Thromboembolic and hemorrhagic adverse events were compared between 207 patients who received low-dose prasugrel (PSG group) and 90 patients who received clopidogrel (CPG group). RESULTS: P2Y12 reaction unit (PRU) values were significantly lower in the PSG group (PSG group vs CPG group, 132.3 ± 76.9 vs 238.1 ± 69.1; P < .001); the percentage of inhibition was also statistically higher in the PSG group (54.0 ± 26.0% vs 20.8 ± 18.6%; P < .001). Thromboembolic events occurred less frequently in the PSG group than in the CPG group (0.9% vs 6.4%; P = .01), whereas there was no significant difference in the percentage of hemorrhagic complications (0.5% vs 2.2%; P = .22). In the multivariate analysis, clopidogrel as the antiplatelet medication was the sole significant risk factor for thromboembolism in this series of patients undergoing stent-assisted coil embolization. CONCLUSION: Use of low-dose PSG as an antiplatelet premedication is quick, effective, and safe for stent-assisted coil embolization of unruptured intracranial aneurysms. Prasugrel premedication significantly lowered the frequency of thromboembolic events without increasing the risk of hemorrhage.
BACKGROUND: The use of antiplatelet medications to prevent thrombosis in the treatment of cerebral aneurysms with stents has become widely emphasized. OBJECTIVE: To compare low-dose prasugrel with clopidogrel in stent-assisted coil embolization of intracranial aneurysms. METHODS: This is a retrospective review of 311 aneurysms from 297 patients who underwent stent-assisted endovascular coil embolization of unruptured intracranial aneurysm between November 2014 and March 2017. Thromboembolic and hemorrhagic adverse events were compared between 207 patients who received low-dose prasugrel (PSG group) and 90 patients who received clopidogrel (CPG group). RESULTS:P2Y12 reaction unit (PRU) values were significantly lower in the PSG group (PSG group vs CPG group, 132.3 ± 76.9 vs 238.1 ± 69.1; P < .001); the percentage of inhibition was also statistically higher in the PSG group (54.0 ± 26.0% vs 20.8 ± 18.6%; P < .001). Thromboembolic events occurred less frequently in the PSG group than in the CPG group (0.9% vs 6.4%; P = .01), whereas there was no significant difference in the percentage of hemorrhagic complications (0.5% vs 2.2%; P = .22). In the multivariate analysis, clopidogrel as the antiplatelet medication was the sole significant risk factor for thromboembolism in this series of patients undergoing stent-assisted coil embolization. CONCLUSION: Use of low-dose PSG as an antiplatelet premedication is quick, effective, and safe for stent-assisted coil embolization of unruptured intracranial aneurysms. Prasugrel premedication significantly lowered the frequency of thromboembolic events without increasing the risk of hemorrhage.
Authors: Samuel Pearce; Julian T Maingard; Hong Kuan Kok; Christen D Barras; Jeremy H Russell; Joshua A Hirsch; Ronil V Chandra; Ash Jhamb; Vincent Thijs; Mark Brooks; Hamed Asadi Journal: Clin Neuroradiol Date: 2021-03-01 Impact factor: 3.649
Authors: J M Ospel; P Brouwer; F Dorn; A Arthur; M E Jensen; R Nogueira; R Chapot; F Albuquerque; C Majoie; M Jayaraman; A Taylor; J Liu; J Fiehler; N Sakai; K Orlov; D Kallmes; J F Fraser; L Thibault; M Goyal Journal: AJNR Am J Neuroradiol Date: 2020-09-17 Impact factor: 3.825
Authors: F Cagnazzo; P Perrini; P-H Lefevre; G Gascou; C Dargazanli; C Riquelme; I Derraz; D di Carlo; A Bonafe; V Costalat Journal: AJNR Am J Neuroradiol Date: 2019-03-14 Impact factor: 3.825
Authors: Hans Henkes; Pervinder Bhogal; Marta Aguilar Pérez; Tim Lenz-Habijan; Catrin Bannewitz; Marcus Peters; Christina Sengstock; Oliver Ganslandt; Pedro Lylyk; Hermann Monstadt Journal: Interv Neuroradiol Date: 2019-06-27 Impact factor: 1.610
Authors: Damian Kocur; Piotr Paździora; Nikodem Przybyłko; Wojciech Kukier; Jan Baron; Adam Rudnik Journal: Wideochir Inne Tech Maloinwazyjne Date: 2019-10-17 Impact factor: 1.195
Authors: Marta Aguilar Perez; Victoria Hellstern; Carmen Serna Candel; Christina Wendl; Hansjörg Bäzner; Oliver Gansladt; Hans Henkes Journal: Stroke Vasc Neurol Date: 2020-09-12